in ,

DOD Taps Continuus for Onshore Production of Active Pharmaceutical Ingredients

Continuus Pharmaceuticals
Continuus Pharmaceuticals

Continuus Pharmaceuticals has secured a $69.3M contract with the Department of Defense to use its integrated continuous manufacturing technology for developing critical active pharmaceutical ingredients and final dosage form medicines used for COVID-19 treatment.

The company will employ the ICM, a fully-automated, small-footprint facility, to provide the U.S. with domestic production capability in support of caring for COVID-19 patients, DOD said Friday.

The U.S. currently sources critical APIs and their starting materials from companies outside the country.

With the investment, Continuus will enable onshore manufacturing of three critical APIs and their final dosage forms. The company will also use the ICM technology to streamline logistical processes for future health care needs.

DOD issued the contract in coordination with the Department of Health and Human Services and under the Coronavirus Aid, Relief, and Economic Security Act.

ExecutiveBiz Logo

Sign Up Now! ExecutiveBiz provides you with Daily Updates and News Briefings about Contract Awards


Written by Nichols Martin

a staff writer at Executive Mosaic, produces articles on the federal government's technology and business interests. The coverage of these articles include government contracting, cybersecurity, information technology, health care and national security.

S3 AeroDefense
S3 International Changes Name to Reflect Aerospace & Defense Market Vision
Tenable Earns Common Criteria Certification From Nat’l Info Assurance Partnership